Table 2 Linear mixed-effects model for repeated measures (MMRM) of the domains and functional scales of health-related quality of life questionnaires in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
Questionnaire | Domains and functions (abbreviation) | Second-line or later pembrolizumab (n = 19) | Maintenance avelumab (n = 13) | Adjuvant nivolumab (n = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | MID# | Estimated mean change per a month (standard error) | P value## | Baseline | MID# | Estimated mean change per a month (standard error) | P value## | Baseline | MID# | Estimated mean change per a month (standard error) | P value## | ||
EORTC QLQ-C30 | |||||||||||||
Global health status/QoL | 54 ± 21 | ± 10 | 1.31 (0.56) | 0.022 | 62 ± 26 | ± 10 | -0.63 (0.94) | 0.51 | 63 ± 19 | ± 10 | 0.27 (0.60) | 0.66 | |
Physical functioning (PF) | 72 ± 24 | ± 10 | 1.02 (0.41) | 0.015 | 77 ± 18 | ± 10 | 0.20 (0.59) | 0.73 | 74 ± 20 | ± 10 | 0.50 (0.37) | 0.18 | |
Role functioning (RF) | 72 ± 24 | ± 10 | 1.18 (0.43) | 0.007 | 83 ± 16 | ± 10 | -0.15 (0.48) | 0.76 | 83 ± 18 | ± 10 | 0.12 (0.31) | 0.69 | |
Emotional functioning (EF) | 75 ± 24 | ± 10 | 0.81 (0.43) | 0.06 | 81 ± 20 | ± 10 | -0.34 (0.37) | 0.36 | 79 ± 23 | ± 10 | 0.57 (0.47) | 0.23 | |
Cognitive functioning (CF) | 72 ± 24 | ± 10 | 0.25 (0.44) | 0.56 | 72 ± 18 | ± 10 | 0.34 (0.57) | 0.56 | 77 ± 24 | ± 10 | 0.44 (0.58) | 0.46 | |
Social functioning (SF) | 82 ± 21 | ± 10 | -0.62 (0.47) | 0.19 | 85 ± 20 | ± 10 | -0.85 (0.62) | 0.18 | 78 ± 22 | ± 10 | 0.42 (0.26) | 0.11 | |
FACT-G | |||||||||||||
Physical well-being (PWB) | 22 ± 5.5 | ± 2.8 | 0.28 (0.10) | 0.005 | 22 ± 4.3 | ± 2.2 | 0.09 (0.11) | 0.42 | 21 ± 4.7 | ± 2.4 | 0.29 (0.11) | 0.012 | |
Social/family well-being (SWB) | 14 ± 6.7 | ± 3.4 | -0.27 (0.11) | 0.017 | 12 ± 6.3 | ± 3.2 | -0.43 (0.22) | 0.056 | 13 ± 4.9 | ± 2.5 | 0.26 (0.18) | 0.15 | |
Emotional well-being (EWB) | 16 ± 4.5 | ± 2.3 | 0.14 (0.09) | 0.120 | 17 ± 4.1 | ± 2.2 | 0.35 (0.15) | 0.019 | 18 ± 4.7 | ± 2.4 | 0.26 (0.14) | 0.064 | |
Functional well-being (FWB) | 16 ± 5.5 | ± 2.8 | 0.39 (0.13) | 0.005 | 14 ± 8.8 | ± 4.4 | -0.82 (0.32) | 0.014 | 16 ± 6.9 | ± 3.5 | -0.19 (0.19) | 0.32 | |
FACT-G total score | 68 ± 13 | ± 6.5 | 0.56 (0.22) | 0.011 | 64 ± 17 | ± 8.5 | -0.94 (0.44) | 0.14 | 68 ± 16 | ± 8.0 | 0.53 (0.35) | 0.14 | |
SF-8 | |||||||||||||
Physical function (PF) | 41 ± 12 | ± 6.0 | 0.52 (0.20) | 0.011 | 45 ± 7.6 | ± 3.8 | -0.19 (0.28) | 0.51 | 42 ± 12 | ± 6.0 | -0.16 (0.20) | 0.43 | |
Role physical (RP) | 41 ± 11 0.59 (0.21) | ± 5.5 | 0.007 | 46 ± 8.5 | ± 4.3 | -0.32 (0.26) | 0.22 | 43 ± 13 | ± 6.5 | 0.09 (0.17) | 0.58 | ||
Bodily pain (BP) | 48 ± 10 | ± 5.0 | 0.71 (0.23) | 0.002 | 56 ± 7.6 | ± 3.8 | -0.59 (0.27) | 0.34 | 50 ± 7.5 | ± 3.8 | -0.02 (0.29) | 0.95 | |
General health (GH) | 45 ± 8.0 | ± 4.0 | 0.68 (0.19) | < 0.001 | 51 ± 8.0 | ± 4.0 | -0.24 (0.27) | 0.39 | 48 ± 6.9 | ± 3.5 | 0.03 (0.15) | 0.86 | |
Vitality (VT) | 47 ± 7.2 | ± 3.6 | 0.55 (0.17) | 0.002 | 51 ± 8.3 | ± 4.2 | -0.48 (0.25) | 0.061 | 48 ± 7.8 | ± 3.9 | 0.37 (0.16) | 0.035 | |
Social functioning (SF) | 44 ± 11 | ± 5.5 | -0.62 (0.47) | 0.16 | 50 ± 9.1 | ± 4.6 | -0.43 (0.27) | 0.077 | 44 ± 13 | ± 6.5 | -0.10 (0.21) | 0.63 | |
Role emotional (RE) | 43 ± 9.2 | ± 4.6 | 0.44 (0.17) | 0.009 | 49 ± 7.7 | ± 3.9 | -0.51 (0.28) | 0.28 | 45 ± 8.7 | ± 4.4 | 0.01 (0.19) | 0.93 | |
Mental health (MH) | 46 ± 8.0 | ± 4.0 | 0.50 (0.15) | 0.001 | 52 ± 6.9 | ± 3.5 | -0.40 (0.22) | 0.078 | 47 ± 9.4 | ± 4.7 | 0.10 (0.18) | 0.60 | |
Physical component summary (PCS) | 42 ± 10 | ± 5.0 | 0.64 (0.21) | 0.003 | 47 ± 7.5 | ± 3.8 | -0.34 (0.25) | 0.18 | 44 ± 10 | ± 5.0 | -0.04 (0.17) | 0.82 | |
Mental component summary (MCS) | 46 ± 8.2 | ± 4.1 | 0.32 (0.16) | 0.055 | 50 ± 6.4 | ± 3.2 | -0.33 (0.25) | 0.18 | 46 ± 7.8 | ± 3.9 | 0.12 (0.18) | 0.51 | |
